. Retinalneovascularization(NV)representsanimportantrisk factorforseverevisionlossinpatientswithproliferative diabeticretinopathy(PDR).About60%ofpatientswithPDR respondtopanretinalphotocoagulation(PRP)withregression ofNVwithin3mo [2] .However,manypatientsrequire additionallasertreatment,and4.5%ultimatelyrequirepars planavitrectomydespitePRP [3] . [12] [13] ,asfollows:1)presenceof moderatetosevereneovascularizationonthedisc(NVDs) with1/4-1/3discareainsizeorlarger;2)lessextensive NVD,ifvitreousorpre-retinalhemorrhagingwaspresent;3) NVofelsewhere(NVE) 逸1/2discarea,ifvitreousor pre-retinalhemorrhagingwaspresent. PRPcurrentlyisthemainstayandgoldstandardwell-known principaltherapyforPDRsincetheDiabeticRetinopathy Studywaspublished [14] .Itisestimatedthatabout60%PDR patientsrespondtolaserPRPwithretinalNVregression within3mo.AlthoughPRPreducesthepossibilityofsevere visualloss,itisadestructiveprocedure,andithasseveral sideeffects,suchasmacularedema,constrictedvisualfield andlaser-inducedVH.Manydiabeticpatientsneed additionallasertherapyand4.5%ofthemeventuallyrequire vitrectomysurgerydespitelaserPRP [3] .Especially,additional lasertherapyorsurgicalinterventionhasbeennecessary afterPRPperformanceforhigh-riskPDR.Moreover,NV regressionmaytakeseveralweeksaftercompletionofPRP, andNVcontinuestogrowdespitethefirstsessionofPRPin one-thirdofpatients.Therefore,VHmayleadtovisualloss andprecludecompletelaserPRPinthesepatients.Recent reportshaveshownthatVEGFplaysakeyroleinNVofthe eye,andthatintravitrealanti-VEGFinjectioncanleadto regressionofNVinPDR,neovascularage-relatedmacular degeneration,centralretinalveinobstructionandirisNV [15] [16] [17] . Itmayplayasanewtherapeuticoptionoranadjuvantagent toPRPinsomepatientsofPDR,suchaswhenVHprecludes [4, 7, 10] . Althoughbothtreatmentsareassociatedwithsignificant regressionofactiveNV,nosignificantBCVAchangewas observedaftertreatmentinthePRP-Plusgroup,whileslight visualacuityworseningwasobservedinpartialpatients treatedonlywithPRP.Macularedemaistheleadingcause ofvisuallossindiabeticretinopathypatients [18] .The intravitrealanti-VEGFinjection canreducemacular interstitialfluidoredemathat,evenwhensubclinical,might causeretinalfunctionalimpairment [19] [20] [21] .However,inthe currentstudy,Itisstatedthattheearlyvisualgainsdueto IVBwerenotmaintained5yaftertreatment [22] .Inourstudy, nodifferenceinaverageCSMTemergedbetweenthegroups throughoutthe24-weekfollow-upperiod.Ofnote,ourstudy includedmainlypatientswithoutclinicallysignificant macularedema,andinthesepatients,atrendtowardsCSMT decreasewasobservedinthePRP-Plusgroup,whilea CSMTincreasewasobservedineyestreatedwithPRP alone.Inthepresentstudy,inbothgroups,BCVAremained relativelystableanddidnotdifferfrombaseline,ofnote,a significantimprovementinBCVAwasobservedinthe PRP-Plusgroupafterintravitrealanti-VEGFtreatment comparedwithPRPgroup.Thisdifferencemaybeexplained by theclearingofpre-existingpreretinalorVHand improvementindiabeticmacularedema.Itisassumedthat theadjunctiveuseofbevacizumabwithPRPwouldhavethe potentialtoprevent,atleastinpart,thedevelopmentof macularedemainpatients. NodifferenceinIOPandlensgradingscorebetweenthetwo groupswasobservedthroughoutthestudy,andnosignificant changeinIOPwasobservedatanystudyvisitcompared withbaselineineithergroup.Theresultsofourstudyare consistentwithdatafromotherstudiesregardingnoapparent associationbetweenIVBinjectionandincreaseinIOP, cataractdevelopment/progression,oranincreasedrateof endophthalmitisandthestudydrug [23] .Butsystemicandlocal adverseeventsaboutIVBmustbemonitoredforlongterm, becausethecurrentstudysuggestthatmultipleintravitreal injectionscouldbeassociatedwithsustainedIOPelevation [24] . Andintheliterature,aseriouscomplicationofbranched retinalarteryobstructionafterIVBinjectionwasobservedin onepatientwithPDR,possiblyduetothethromboembolic effectsofbevacizumab [8] . Therearealsomorecomfortandlessretinalfunctionalloss forPRP-plusintravitrealanti-VEGFinjectionincomparison to PRPaloneforhigh-riskPDRtreatment [6, [25] [26] .In conclusion,bevacizumabappearstohaveaplaceinthe treatmentofPDR.Theobservedanatomic(byophthalmic examinationandFA)andvisualacuityimprovementsafter combinedIVBinjectionandPRPdemonstratedthatitwasa safeandusefulalternativeoradjunctivetreatmentfor high-riskPDR.Thelimitationsofthispresentstudyincluded thefactthatithadrelativelysmallnumberofpatients (sufficientforstatisticalpurposes)andshort-termfollow-up period.Along-termprospectivestudyisneededtoconfirm themaintenanceoftherapeuticbenefitsuggestedinthisstudy andtodeterminetheoptimaldosingregimen.Evaluationof possiblelong-termocularandsystemicadverseeffectsisalso essential.Furtherrandomizedstudieswillstrengthenthe currentfindings,givingevidencetoguidetreatmentchoices inthemanagementofhigh-riskPDR.
